Vaginal microbiota and human papillomavirus infection among young Swedish women

Liqin Cheng1,5, Johanna Norenhag2,5, Yue O. O. Hu1,5, Nele Brusselaers1, Emma Fransson1,2, Andreas Åhrlund-Richter3, Unnur Guðnadóttir1, Pia Angelidou1, Yinghua Zha1, Marica Hamsten1, Ina Schuppe-Koistinen1,4, Matts Olovsson2, Lars Engstrand1,4 and Juan Du5,6

Human papillomavirus (HPV) infection is one of the most common sexually transmitted diseases. To define the HPV-associated microbial community among a high vaccination coverage population, we carried out a cross-sectional study with 345 young Swedish women. The microbial composition and its association with HPV infection, including 27 HPV types, were analyzed. Microbial alpha-diversity was found significantly higher in the HPV-infected group (especially with oncogenic HPV types and multiple HPV types), compared with the HPV negative group. The vaginal microbiota among HPV-infected women was characterized by a larger number of bacterial vaginosis-associated bacteria (BVAB), Sneathia, Prevotella, and Megasphaera. In addition, the correlation analysis demonstrated that twice as many women with non-Lactobacillus-dominant vaginal microbiota were infected with oncogenic HPV types, compared with L. crispatus-dominated vaginal microbiota. The data suggest that HPV infection, especially oncogenic HPV types, is strongly associated with a non-Lactobacillus-dominant vaginal microbiota, regardless of age and vaccination status.

npj Biofilms and Microbiomes (2020) 6:39 ; https://doi.org/10.1038/s41522-020-00146-8

INTRODUCTION

Infection with human papillomavirus (HPV) is among the most common sexually transmitted diseases in the world, with the highest prevalence among women below 25.1,2 HPV infection is the main cause of cervical cancer and is related to many other cancers, including head and neck cancer.3 Depending on their oncogenic potential, mucosal HPV types can be divided into oncogenic HPVs, such as those observed in cancer cases, and non-oncogenic HPVs, mainly found in condyloma.4 The two most common HPV types in cervical cancer are HPV16 and 18, which are responsible for ~70% of cervical cancer cases worldwide.5,6 At a youth clinic in Stockholm, Sweden, we have previously shown an overall cervical HPV prevalence of over 70% among young girls in Sweden.7,8 The HPV vaccination program was gradually introduced to Sweden from 2007. Since 2012, all girls between the ages of 10 and 12 years are offered free vaccination with the quadrivalent Gardasil vaccine against HPV6, 11, 16, and 18, in a school-based vaccination program and catch-up vaccination. The vaccination ratio has increased dramatically from 10.7% (2008–2010) to 82.1% (2017–2018).9 The prevalence of HPV types covered in the vaccine has dropped significantly in vaccinated women compared with non-vaccinated women, underlining the importance and success of the vaccination program.7,9,8 However, the total HPV prevalence caused by HPV types that are not covered by the vaccine is still high, indicating that more interventions to reduce these HPV infections are still needed.7,8 Further, the influence of the HPV vaccine on vaginal microbiota has not been thoroughly investigated, especially in a high vaccination coverage country.

An increasing number of studies suggest that vaginal microbiota play an essential role in women’s health, specifically in sexually transmitted diseases, pelvic inflammatory disease, and adverse obstetric outcomes.10–13 The vaginal microbiota is primarily dominated by one of the four most common Lactobacillus species: Lactobacillus crispatus, Lactobacillus iners, Lactobacillus gasseri, and Lactobacillus jensenii.14–16 In addition, some women may have vaginal microbiota dominated by bacterial species other than Lactobacilli, such as Prevotella, Gardnerella, and Sneathia.17–19 The general clinical diagnostic approaches worldwide for bacterial vaginosis (BV), which is also characterized by a lack of Lactobacilli but a higher quantity of aerobic and anaerobic bacteria, are the Amsel criteria and the Nugent score, based on wet smear diagnosis and Gram staining. However, the sensitivity and specificity for both methods are moderate.19 Molecular diagnosis, such as 16S rRNA gene sequencing, enables the microbiota determination at the species level. Bacterial vaginosis associated bacteria (BVAB), including BVAB 1, 2, and 3, have been identified from the vaginal fluid of women with bacterial vaginosis and could serve as potential vaginosis biomarkers.20–22 Unfortunately, BVAB have not been included in the 16S amplicon sequencing-based vaginal microbiota studies related to HPV, probably due to taxonomic information missing from the popular 16S rRNA databases, with most studies on BVAB being based on qPCR sequencing.

Cross-sectional studies and very few longitudinal studies from other countries showed that L. crispatus is observed more frequently in women without HPV infection and cancer lesions, whereas L. iners and non-Lactobacillus species are more common in HPV-infected women and patients with cancer lesions.23–26 However, there are no data available yet in the Nordic countries on the vaginal microbiota composition and its relationship with HPV infection, using a sequencing method. Thus, we initiated a cross-sectional study to assess the association between the vaginal microbiota and 27 HPV types in Sweden. In addition,
because HPV infection has the highest prevalence among young women, we designed our study to focus on women below 30 years old.

RESULTS
Participant characteristics in the study cohort
As seen from the flowchart of Supplementary Fig. 1, a total of 345 participants were enrolled in this study, in which 33 women were excluded from the study due to antibiotics usage within the past three months (n = 18) or incomplete clinical information (n = 15). Samples with low DNA concentration and low reads in sequencing (n = 55) were excluded from downstream microbiota analysis. Eventually, 169 samples from women visiting the youth clinic and 88 samples from women attending the cervical screening were included for analyses (Supplementary Fig. 1).

The HPV prevalence of the samples from the youth clinic have been published previously. From the 169 women visiting the youth clinic and 88 samples from women attending the cervical screening were included for analyses (Supplementary Fig. 1).

Eventually, 169 samples from women visiting the youth clinic and 88 samples from women attending the cervical screening were included for analyses (Supplementary Fig. 1).

The HPV prevalence of the samples from the youth clinic have been published previously. From the 169 women visiting the youth clinic, the prevalence of any HPV and oncogenic HPV were 67.5% and 59.8%, respectively (Supplementary Table 1). Among the 88 participants attending the cervical screening, the overall HPV prevalence was 34.1%, with HPV56 (6.8%), HPV45 (4.5%), and HPV52 (4.5%) as the three most common oncogenic HPV types (Supplementary Fig. 2a and Supplementary Table 1). The HPV vaccine appeared to provide full protection to the participants in the cervical screening, with no one (including the non-vaccinated ones) being infected with the HPV types covered in the quadrivalent HPV vaccine (Supplementary Fig. 2a). Moreover, when compared vaccinated with non-vaccinated women, none of the prevalence difference (any HPV, oncogenic HPV, HPV covered in vaccine, probably oncogenic HPV, and non-oncogenic HPV) reached statistical significance according to Fisher’s exact test (Supplementary Fig. 2b). Both the HPV infection prevalence and vaccine coverage in the cervical screening samples were significantly lower than that of the youth clinic samples (34.1% vs. 67.5%, p < 0.0001 and 61.4% vs. 81.1%, p < 0.001, respectively; Figs. 1a, b and Supplementary Table 1).

Vaginal microbiota was comparable in women from the youth clinic and the cervical screening.

We continued to compare the microbial community composition from the two sources. Alpha diversity analysis of the microbiota profile based on Shannon and Faith’s diversity suggested no significant difference between the two sources (p = 0.064 and 0.138, respectively), while Chao 1 analysis showed a significant difference between the two sources (p = 0.004; Fig. 1c and Supplementary Figs. 3a and 4a). The bacterial community profiles in the samples from the youth clinic and the cervical screening samples were comparable, with overall 32.7% L. crispatus dominated, 30.4% L. iners dominated, and 33.5% non-Lactobacillus-dominated (Supplementary Table 1). Furthermore, no significant difference was observed in the ratio of the four community types based on sample source (Supplementary Table 2). In order to address the relationship between vaginal microbiota and HPV infection, we combined the samples from the youth clinic and the cervical screening for all the following analysis.

Principal coordinates analysis (PCoA) based on the Bray-Curtis distance demonstrated that all the samples were mainly separated into L. crispatus, L. iners, and non-Lactobacillus-dominated categories, and only a few samples were dominated by other Lactobacillus species (Fig. 1d). Detail distributions of the amplicon sequence variants (ASVs) from the major genera and species including Gardnerella, Prevotella, Sneathia, and BVABs were shown in Supplementary Fig. 5a. Furthermore, we also performed the PCoA based on the UniFrac phylogenetic distance, which separated all the samples into Lactobacillus-dominated and non-Lactobacillus-dominated categories (Supplementary Fig. 6a). Since Lactobacillus species are phylogenetically close, Lactobacillus-dominated samples clusted together in phylogenetic distance-based PCoA (Supplementary Fig. 3d).
Young women with HPV infection had higher vaginal microbial diversity. In general, *L. crispatus* and *L. iners* were found to be the most dominant species among both HPV-uninfected and HPV-infected participants (Fig. 2a, b). The majority of non-*Lactobacillus* dominated samples consisted of a large proportion of bacteria belonging to the genera *Gardnerella, Prevotella, Sneathia*, and BVABs (Fig. 2a, b). The Shannon, Chao 1, and Faith’s diversity analyses all found significantly higher microbial alpha diversity among HPV-infected women than those without HPV infection ($p = 0.0006, 0.001$, and $0.0005$, respectively; Fig. 2c and Supplementary Figs. 3b and 4b). The ratios of the four vaginal microbiota compositions were significantly different between women with and without HPV infection ($p = 0.043$) (Supplementary Table 2). Notably, the non-*Lactobacillus* community profile was more prevalent among HPV-infected women, compared with uninfected women according to Fisher’s exact test ($p = 0.011$; Fig. 2a, b and Supplementary Table 2). However, the PCoA analysis based on the Bray–Curtis distance showed no clear separation between HPV-uninfected and HPV-infected groups based on their microbial community compositions (Supplementary Fig. 5b). The PCoA based on the UniFrac phylogenetic distance also did not separate...
Young women with oncogenic HPV infection had higher vaginal microbial diversity

Microbial alpha diversity based on Shannon, Chao 1, and Faith’s diversity analyses displayed significantly higher diversity of women infected with both oncogenic and non-oncogenic HPV, than HPV-uninfected women (p = 0.00008, 0.0002, and 0.0005, respectively; Fig. 3a and Supplementary Figs. 3c and 4c). The same holds true when comparing women with only oncogenic HPV infection with those without HPV infection (p = 0.041, 0.030, and 0.025, respectively; Fig. 3a and Supplementary Figs. 3c and 4c). Shannon and Faith’s diversity analyses also displayed significant differences between women infected with both oncogenic and non-oncogenic HPV, and women with only oncogenic HPV infection (p = 0.013 and 0.03, respectively), but no significant difference among other groups was observed. The PCoA analysis showed no clear separation of samples with HPV-uninfected, infected with both oncogenic and non-oncogenic HPV, and only oncogenic HPVs (Supplementary Figs. 5c, d and 6d). We further divided samples according to their HPV phylogenetic groups and evaluated the association of HPVs phylogenetic groups with vaginal microbiome composition. However, PCoA based on the UniFrac phylogenetic distance showed no clear separation among samples from different HPV phylogenetic groups either (Supplementary Fig. 6e).

Young women with multiple HPV types had higher vaginal microbial diversity

We further analyzed whether the number of infected HPV types affected vaginal microbial diversity. Compared with women without HPV infection, all the analyses showed that women infected with multiple HPV types had significantly higher microbiota diversity (p = 0.0004 for Shannon, 0.0007 for Chao 1, and 0.0008 for Faith’s diversity, respectively; Fig. 3b and Supplementary Figs. 3d and 4d). Only the Shannon analysis displayed significantly higher microbiota diversity in women infected with single HPV type than in women without HPV infection (p = 0.042; Fig. 3b and Supplementary Figs. 3d and 4d).

Young women with certain HPV types had higher microbial diversity

Detailed information on 27 HPV types allowed us to compare the vaginal microbiome from participants infected with different HPV types. As listed in Fig. 3c, among the HPV types with enough women in the group for analysis (n > 5), women infected with HPV39, 42, and 56 had significantly higher diversity compared with HPV-uninfected group in the Shannon analysis, which indicates that infection by these three HPV types tends to be related to higher diversity in vaginal microbiota (Fig. 3c). HPV39 and 58 in the Chao 1 analysis and HPV39, 58, and 59 in the Faith’s diversity analysis were the HPV types showing significantly higher diversity compared with the HPV-uninfected group (Supplementary Figs. 3e and 4e).

Certain bacterial species were related to HPV infection

To identify potential bacterial biomarkers for HPV infection, we compared the relative abundance of all the bacteria from women with and without HPV infection. From statistical analysis on microbiota taxonomy, we observed that BVAB 1, BVAB 2, Sneathia, Prevotella, and Megasphaera were significantly more prevalent among HPV-infected women than HPV-uninfected women (q = 0.0038, 0.048, 0.048, 0.048, and 0.048, respectively; Fig. 4).
Interestingly, BVAB1 almost exclusively present in the vaginal microbiota of HPV-infected young women, indicating a very close relationship between BVAB1 and HPV infection (Fig. 2a, 2b).

Age and HPV vaccine had little influence on vaginal microbial diversity
In general, HPV vaccine coverage declined with increasing age, probably due to the lag time of the national HPV vaccination program in Sweden. Vaccination coverage dropped from 100% among young women age 14–17 to 70–90% among those age 18–24, and 20–60% among those age 25–29 (Fig. 5a). Irrespective of vaccination status, HPV prevalence increased from age 14 (0%), and peaked around the age of 18–26 (~50% and above) and dropped to ~10% at age of 29 (Fig. 5b). Oncogenic HPV types accounted for most of the HPV-infected cases in each age group and followed similar trend as the total HPV infection (Fig. 5b).

However, the vaginal microbiota diversity analysis according to age showed no difference among the age groups in all three analysis (Fig. 5c and Supplementary Figs. 3f and 4f). Similarly, microbial alpha diversity of vaccinated women also showed no significant difference from non-vaccinated women (Fig. 5d and Supplementary Figs. 3g and 4g). In addition, these data were supported by no significant difference was shown in the ratio of the four community types among samples with different age and vaccine status (Supplementary Table 2). All together, these data suggested that age and HPV vaccine status had little influence on microbial composition.

Age, vaccine status, and vaginal microbiota showed correlation to HPV infection
We continued to evaluate the correlation of age, vaccination status, and vaginal microbiota with the risk of HPV or oncogenic HPV infection. The significantly higher HPV prevalence in the youth clinic compared with the cervical screening samples, contributed to the highest ratio of any HPV, oncogenic HPV, or multi-type HPV infection observed among the 19–24 age group (Table 1 and Supplementary Table 3). HPV vaccination demonstrated a significant protective effect against multiple HPV infection (p < 0.001, Supplementary Table 3).

Logistic regression analysis showed that age and the sample source were significantly associated with the risk of being HPV-infected. The highest HPV risks after adjustment were among women in the 19–24 age group (odds ratios: OR = 4.0, 95% confidence intervals: CI 1.9–8.7), compared with women below 18, and women from the youth clinic (OR = 5.4, 95% 2.4–12.2), compared with the cervical screening samples (Table 1). Similar associations were observed for both oncogenic HPV and non-oncogenic HPV types. After adjustment for the other variables, age (19–24 years old) and sample source (youth clinic), and non-Lactobacillus dominated remained significantly associated with infections with oncogenic HPV, multiple HPV, and multiple oncogenic HPV (Table 1 and Supplementary Table 3). Moreover, HPV vaccine halved the risk of oncogenic HPV infection (OR = 0.5, 95% CI 0.2–1.00) (Table 1 and Supplementary Table 3).

Non-Lactobacillus-dominated vaginal microbiota showed more than twice the risk of having an infection with any HPV, oncogenic HPV, and non-oncogenic HPV infection than those with L. crispatus-dominated microbiota (OR = 2.0, 95% CI 1.1–3.7 for HPV infection; OR = 2.1, 95% CI 1.2–4.0 for oncogenic HPV infection; and OR = 2.2, 95% CI 1.1–4.8 for non-oncogenic HPV infection). After adjustment for the other variables listed in the table, the risk of oncogenic HPV infection was OR = 2.0 (95% CI 1.0–3.9) in non-Lactobacillus-dominated samples, compared with L. crispatus-dominated samples. The difference became more pronounced when only women with multiple HPV and multiple...
oncogenic HPV types were included in the analysis (OR = 2.5, 95% CI 1.1–5.9 for multiple HPV infection; OR = 2.4, 95% CI 1.0–5.8 for multiple oncogenic HPV infection; Table 1 and Supplementary Table 3).

**DISCUSSION**

This is a large cross-sectional study for evaluating the relationship between vaginal microbiota and HPV infection. It is also the study carried out in a high HPV vaccine coverage country with young women, using sequencing technology. This study brings essential comparative data and a geographic contribution to the worldwide vaginal microbiome researches. Overall, a significantly higher microbiota diversity was observed in women infected with any HPV, oncogenic HPV, and multiple HPV types, than in women not infected with HPV (Table 1 and Figs. 2, 3 and Table 1). Further, we also demonstrated a slight but significantly increased microbiota diversity among women infected with oncogenic HPV in all the age groups (Kruskal–Wallis test; p > 0.05). Microbial alpha diversity based on Shannon index of all the samples showed no significant difference among age groups (Kruskal–Wallis test; p > 0.05). Data were presented as mean values with standard deviations.

...
The risk of human papillomavirus (HPV) by different characteristics.

|                      | Unadjusted OR (95% CI) | Adjusted OR (95% CI) | Adjusted OR (95% CI) |
|----------------------|------------------------|----------------------|----------------------|
| HPV                  |                        |                      |                      |
| Oncogenic HPV        | 5.1 (3.0–9.2)          | 4.1 (2.4–6.9)        | 1.7 (1.0–2.9)        |
| Non-oncogenic HPV    | 1.8 (0.0–11.4)         | 0.5 (0.1–2.1)        | 0.2 (0.0–1.1)        |
| HPV +                |                        |                      |                      |
| 18 years             | Reference              | Reference            | Reference            |
| –                    | Reference              | Reference            | Reference            |
| HPV –                | 1.0 (0.4–2.1)          | 0.5 (0.2–2.1)        | 0.2 (0.0–1.1)        |
| HPV vaccination      |                        |                      |                      |
| No                   | Reference              | Reference            | Reference            |
| –                    | Reference              | Reference            | Reference            |
| HPV +                | 1.7 (0.8–3.4)          | 0.9 (0.4–2.1)        | 0.2 (0.0–1.1)        |
| HPV –                | 1.0 (0.4–2.1)          | 0.5 (0.2–2.1)        | 0.2 (0.0–1.1)        |
| Screening cohort     |                        |                      |                      |
| Yes                  | Reference              | Reference            | Reference            |
| –                    | Reference              | Reference            | Reference            |
| HPV +                | 2.4 (1.4–4.1)          | 1.3 (0.6–2.9)        | 0.3 (0.0–1.9)        |
| HPV –                | 1.0 (0.4–2.1)          | 0.5 (0.2–2.1)        | 0.2 (0.0–1.1)        |
| Vaginal microbiota   |                        |                      |                      |
| L. iners             | 1.9 (0.4–8.1)          | 0.9 (0.2–3.2)        | 0.2 (0.0–1.1)        |
| Lactobacilli         | 1.9 (0.4–8.1)          | 0.9 (0.2–3.2)        | 0.2 (0.0–1.1)        |
| Others               | 2.0 (1.1–3.9)          | 2.1 (1.2–4.9)        | 2.0 (1.0–3.9)        |
| All the data is presented as odds ratio (OR) and 95% confidence interval (CI) calculated by multivariable logistic regression. The risk of any subgroup of HPV + in all models are adjusted for age, source, age, and vaccination status. A statistically significant difference (<0.05). |

In conclusion, this is a large cross-sectional study on young Swedish women with high HPV vaccination coverage. It demonstrates the strong association between non-Lactobacillus-dominated vaginal microbiota and HPV infection, including any HPV, oncogenic HPV infection, and multiple HPV types. It also indicates that HPV vaccine has little impact on vaginal microbiota, and bacterial species such as BVABs could potentially be used as a biomarker and target for HPV infection and treatment.
METHODS

Study population
In total, 172 previously described young women and 34 new participants, between the ages of 14 and 22, who visited a youth clinic in Stockholm were included (n = 206). Their samples were collected during the clinical visit either by clinical staff or self-collected with a vaginal swab (FLOQSwabs™, Copan Flock Technologies, Brescia, Italy). Vaginal swab was inserted ~2–3 cm into the vagina and swirled for ~30 s. In addition, 139 study participants between 23 and 29 years were enrolled from the population-based cervical screening at maternal health clinics (n = 133), and from follow-up screening at the gynecological clinic, Uppsala University hospital (n = 6), Uppsala, Sweden. These samples were collected by clinical staff and referred to as the cervical screening samples. Collection methods were compared prior to the study and showed no difference in microbiota composition33. For all the samples, the collection swabs were immediately put inside FluidX tubes (Brooks Life Sciences, Chelmsford, MA, USA) containing 0.8 ml DNA/RNA-shield (Zymo Research, Irvine, CA, USA). DNA was polymerase chain reaction (PCR) amplified with broad-spectrum GP5+/6- primers targeting the HPV L1 region, as well as HPV16 and HPV33 primers targeting the E6 region. The HPV16 E6 primers consist of HPV16E6-Forward (TCAAAAGCCCCTGTGTGTCGA), HPV16E6-3-Reverse (GCTGGGTTTCTCTACGTGTTC). HPV33 E6 primers including HPV33E6-Forward (TCTTGGGCCAGGGCGTGTG), and HPV33E6-Reverse (CTCCTGTGCC TTCATGGGCT) as previously described34,35. The PCR conditions contained initial denaturation at 94 °C for 15 min, followed by 40 cycles of denaturation at 94 °C for 30 s, annealing at 38 °C for 90 s and extension at 71 °C for 80 s, and a final extension step at 71 °C for 4 min. The PCR product was further evaluated using a multiplex bead-based assay on a MAGPIX instrument (Luminex Inc., USA), as reported previously36. Probes for detecting HPV16 E6 (GCTTTGGTGGAGATCATAAG) and HPV33E6p (GAAACGTCACTGGAGGCGAT) were added34,35. Twenty-seven types of HPV were analyzed, including fifteen oncogenic HPVs (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82), six probably oncogenic HPVs (HPV26, 30, 53, 66, 67, 69), and six non-oncogenic HPVs (HPV6, 11, 42, 43, 44, 70)36. DNA extraction

The collection fluid containing the vaginal microbiota was bead-beaten with Matrix E beads (MP Biomedicals, USA), followed by digestion with Proteinase K (20 μl of 20 mg/ml Proteinase K in Proteinase K Storage Buffer for 90 min, 55 °C, 250 rpm) and purification with magnetic beads according to the manufacturer’s guidelines for the ZR-96 Genomic DNA MagPrep kit (Zymo Research, USA), as previously described7,33. Owing to the large sample size and long collection period, DNA extraction was conducted using two versions of the ZR-96 Genomic DNA MagPrep kits. These two versions are from product upgrades that were confirmed to produce comparable microbiota results7,33. In each batch for DNA extraction, we included collection fluid and Zymo Microbial Community DNA Standard (Cat. no. D6300, Zymo Research, USA) as the negative and positive extraction controls, respectively. The purified DNA was stored at −20 °C until further HPV genotyping and microbiota sequencing.

HPV genotyping

DNA was subjected to Illumina MiSeq sequencing platform (Illumina, CA, USA) with MiSeq Reagent Kit v3.

Bioinformatics analysis

A preliminary classification was conducted in R by using DADA2 functions “assignTaxonomy” and “addSpecies” to search ASVs against the Silva database (v. 128)39. As Lactobacillus spp. are dominant in most of the vaginal microbiota, we improved the classification of the ASVs annotated as Lactobacillus by manually BLAST searching them in the National Center for Biotechnology Information (NCBI) database39,41. Moreover, bacterial vaginosis-associated bacteria (BVAB) 1, 2, and 3 were searched from ASVs containing 165 primer-binding regions in the whole genomic sequences and 165 sequences downloaded from other published works20,33-42. The classification of ASVs was further validated by searching BVAB qPCR primer sequences from the BVAB ASVs32. For the classification of Lactobacillus species and BVAB, a maximum of one mismatch was allowed from the alignment.

Phylogenetic tree construction

To facilitate the calculation of Faith’s diversity and UniFrac distance matrix for the downstream analyses, a phylogenetic tree of the ASVs generated in this study was constructed. A multi-alignment of all ASVs was firstly conducted using MAFFT (v.7.407) with the default parameters. The phylogeny was determined using FastTree2 (v.2.18). The generated tree in newick format was then loaded to FigTree for visualization and double-checking whether the phylogenies of the ASVs correspond to their taxonomic annotations.

Alpha- and beta-diversity calculation

The sequence table was rarefied to 4902 reads per sample, before conducting a diversity calculation in R by using the package “vegan” (v. 2.5-6). Alpha diversities (i.e., Shannon, Chao 1 and Faith’s phylogenetic diversity) were calculated using the functions from the same package, which were visualized in violin plots using the package “ggplot2” (v. 3.2.1).
PCoA was conducted based on Bray-Curtis distance matrix and weighted UniFrac distance matrix, using the package "phyloseq" (v. 1.26.1).

Statistics
To test the differences among microbial alpha diversities, the Wilcoxon rank-sum test and Kruskal–Wallis test were employed when comparing diversities between two groups and more than two groups, respectively. Benjamini–Hochberg correction was conducted to decrease the false discovery rate for multiple tests. The same test method was also conducted to identify taxa that are significantly different in proportional abundance between the cohorts. The association between microbiota community structure and HPV, oncogenic HPV, or multiple HPV types was analyzed by multivariable logistic regression, adjusted for age, HPV vaccination status, sample source, and presented as OR and 95% CI, with 95% CI not including OR = 1, indicating statistically significant differences. The relationship among HPV infection, vaginal microbiota, age, sample source, and vaccination status were compared by Fisher’s exact test.

Reporting summary
Further information on research design is available in the Nature Research Reporting Summary linked to this article.

DATA AVAILABILITY
All data generated or analyzed in this study are included in this published article (and the Supplementary Information). The sequencing reads have been submitted to the European Nucleotide Archive (ENA) under accession number PRJEB34755. To download the BVAB sequences and the Lactobacillus species sequences generated in this study, please go to https://github.com/cmtrbio/BVAB-and-Lac-sequences.

CODE AVAILABILITY
The code can be accessed upon request.

Received: 20 March 2020; Accepted: 10 September 2020; Published online: 12 October 2020

REFERENCES
1. Bruno, L. et al. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J. Infect. Dis. 202, 1789–1799 (2010).
2. Smith, J. S., Melendez, A., Rana, R. K. & Pimenta, J. M. Age-specific prevalence of infection with human papillomavirus in females: a global review. J. Adolesc. Health 43, 55–525 (2008).
3. Lehtinen, M., Baussano, I., Paavonen, J., Värsäk, S. & Dillner, J. Eradication of human papillomavirus and elimination of HPV-related diseases - scientific basis for global public health policies. Expert Rev. Vaccines 18, 153–160 (2019).
4. Muñoz, N. et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. New Engl. J. Med. 348, 518–527 (2003).
5. Clifford, G. M., Smith, J. S., Plummer, M., Muñoz, N. & Franceschi, S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer 88, 63–73 (2003).
6. Du, J., Násman, A., Carlson, J. W., Ramqvist, T. & Dalianis, T. Prevalence of human papillomavirus (HPV) types in cervical cancer 2003-2008 in Stockholm, Sweden, before public HPV vaccination. Acta Oncol. 50, 1215–1219 (2011).
7. Ahrlund-Richter, A. et al. Changes in cervical human papillomavirus (HPV) prevalence at a youth clinic in Stockholm, Sweden, a decade after the introduction of the HPV vaccine. Front. Cell. Infect. Microbiol. 9, 59 (2019).
8. Grün, N. et al. Follow-up on oral and cervical human papillomavirus prevalence 2013-2015 in youth at a youth clinic in Stockholm, Sweden. Infect. Dis. 48, 169–170 (2016).
9. Ramqvist, T. et al. Pre-vaccination prevalence of human papillomavirus types in the genital tract of 15-23-year-old women attending a youth health clinic in Stockholm, Sweden. Scand. J. Infect. Dis. 43, 115–121 (2011).
10. Chaban, B. et al. Characterization of the vaginal microbiota of healthy Canadian women through the menstrual cycle. Microbiome 2, 23 (2014).
11. Fettweis, J. M. et al. The vaginal microbiome and preterm birth. Nat. Med. 25, 1012–1021 (2019).
12. Mitra, A. et al. The vaginal microbiota, human papillomavirus infection and cervical intraepithelial neoplasia: what do we know and where are we going next? Microbiome 4, 58 (2016).
13. Onderdonk, A. B., Delaney, M. L. & Fichorova, R. N. The human microbiome during bacterial vaginosis. Clin. Microbiol. Rev. 29, 223–238 (2016).
14. Brotman, R. M. et al. Interplay between the temporal dynamics of the vaginal microbiota and human papillomavirus detection. J. Infect. Dis. 210, 1723–1733 (2014).
15. Petrova, M. I., van den Broek, M., Balzarini, J., Vanderleyden, J. & Lebeer, S. Vaginal microbiota and its role in HIV transmission and infection. FEMS Microbiol. Rev. 37, 762–792 (2013).
16. DiGiulio, D. B. et al. Temporal and spatial variation of the human microbiota during pregnancy. Proc. Natl Acad. Sci. USA 112, 11060–11065 (2015).
17. Ravel, J. et al. Vaginal microbiome of reproductive-age women. Proc. Natl Acad. Sci. USA 108, 4680–4687 (2011).
18. Serrano, M. G. et al. Racial/ethnic diversity in the dynamics of the vaginal microbiome during pregnancy. Nat. Med. 25, 1001–1011 (2019).
19. Coleman, J. S. & Gaydos, C. A. Molecular diagnosis of bacterial vaginosis: an update. J. Clin. Microbiol. 56, e00342-18 (2018).
20. Fredricks, D. N., Fiedler, T. L. & Marrazzo, J. M. Molecular identification of bacteria associated with bacterial vaginosis. New Engl. J. Med. 353, 1899–1911 (2005).
21. Oakley, B. B., Fiedler, T. L., Marrazzo, J. M. & Fredricks, D. N. Diversity of human vaginal bacterial communities and associations with clinically defined bacterial vaginosis. Appl. Environ. Microbiol. 74, 4898–4909 (2008).
22. Ugur, A. R., Tuncer, E. I. & Findik, D. Identification of bacterial vaginosis-associated bacteria in male urethritis: Co-occurrence of Atopobium vaginae and Gardnerella vaginalis. Marshall J. Infect. https://doi.org/10.21161/mjm.180025 (2019).
23. Huang, X. et al. Cervicovaginal microbiome composition correlates with the acquisition of high-risk human papillomavirus types. Int. J. Cancer 143, 621–634 (2018).
24. Norenhag, J. et al. The vaginal microbiota, human papillomavirus and cervical dysplasia: a systematic review and network meta-analysis. JUOG. https://doi.org/10.1111/1471-0528.15854 (2019).
25. Brusselaers, N., Shrestha, S. A., D. E. E. P., van de Wijgert, J. A. N., N. E. K. E. & Verstraeten, H. A. N. S. Vaginal dysbiosis and the risk of human papillomavirus and cervical cancer: systematic review and meta-analysis. Am. J. Obstet. Gynecol. 221, 9–18 (2019).
26. Mitra, A. et al. The vaginal microbiota associates with the regression of untreated cervical intraepithelial neoplasia 2 lesions. Nat. Commun. 11, 1999 (2020).
27. Curty, G. et al. Analysis of the cervical microbiome and potential biomarkers from postpartum HIV-positive women displaying cervical intraepithelial lesions. Sci. Rep. 7, 17364 (2017).
28. Callahan, B. J. et al. Replication and refinement of a vaginal microbial signature of preterm birth in two racially distinct cohorts of US women. Proc. Natl Acad. Sci. USA 114, 9966–9971 (2017).
29. Łaniewski, P. et al. Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women. Sci. Rep. 8, 7593 (2018).
30. Di Paola, M. et al. Characterization of cervico-vaginal microbiota in women developing persistent high-risk Human Papillomavirus infection. Sci. Rep. 7, 10200 (2017).
31. Godoy-Vitorino, F. I. et al. Cervicovaginal fungi and bacteria associated with cervical intraepithelial neoplasia and high-risk human papillomavirus infections in a hispanic population. Front. Microbiol. 9, 2533 (2018).
32. Shannon, B. et al. Association of HPV infection and clearance with cervicovaginal immunology and the vaginal microbiota. Mucosal Immunol. 10, 1310–1319 (2017).
33. Hugert, L. W. et al. A comprehensive automated pipeline for human microbiome sampling, 165 RNA gene sequencing and bioinformatics processing. BioRxiv https://doi.org/10.1101/286915 (2018).
34. Nordfors, C. et al. Human papillomavirus prevalence is high in oral samples of patients with tonsillar and base of tongue cancer. Oral Oncol. 50, 491–497 (2014).
35. Dalianis, T. et al. Human papillomavirus DNA and p16(INK4a) expression in hypopharyngeal cancer and in relation to clinical outcome, in Stockholm, Sweden. Oral Oncol. 51, 857–861 (2015).
36. Martin, M. Culadapt removes adapter sequences from high-throughput sequencing reads. EMBO Rep. 17, 10 (2011).
37. Callahan, B. J. et al. DADA2: high-resolution sample inference from Illumina amplicon data. Nat. Methods 13, 581–583 (2016).
38. Davis, N. M., Proctor, D. M., Holmes, S. P., Relman, D. A. & Callahan, B. J. Simple statistical identification and removal of contaminant sequences in marker-gene and metagenomics data. Microbiome 6, 226 (2018).
39. Quast, C. et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res. 41, D590–D596 (2013).
ACKNOWLEDGEMENTS

We thank Prof. Tina Dalianis and Assoc. Prof. Torbjörn Ramqvist at the Karolinska Institute for kindly helping with the HPV typing. We thank the midwives at the youth clinic in Stockholm and all the personnel at the maternal health clinics and gynecological clinic in Uppsala, for assisting us with this project. This study was supported by The Swedish Foundation for Strategic Research (SSF) [ICA16-0050], Åke Wibergs Foundation [M16-016], M17-0120, and M18-0112], Jeansions Foundation [JS2017-014] and [JS2018-0034], Fredrik and Ingrid Thuring Foundation [2016-00228], the foundations Längmanska Kulturfonden [BA17-0414], Lars Hiertas Minne [F02016-0617], Clas Groschinsky Minnesfond [M18213, M19351], Förenningen för Klinik Mikrobiologi, Svenska Läkaresällskapet [SLS-784981], and the Karolinska Institute. Ferring Pharmaceuticals funded the center where all the experiments and sequencing were carried out.

AUTHOR CONTRIBUTIONS

Conception and design: M.O., L.E., and J.D. Development of methodology: L.C., J.N., J.Y.O.H., E.F., A.A., U.G., M.H., I.S.K., M.O., L.E., and J.D. Analysis and interpretation of data: L.C., J.N., J.Y.O.H. (Bioinformatics analysis), N.B., and J.D. Writing, review, and/ or revision of manuscript: all authors.

FUNDING

Open access funding provided by Karolinska Institute.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information is available for this paper at https://doi.org/10.1038/s41522-020-00146-8.

Correspondence and requests for materials should be addressed to J.D.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2020